MetaVia (MTVA) vs Vistagen Therapeutics (VTGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Vistagen Therapeutics is the larger company by market cap ($10.7 million vs $9.2 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | MTVA | VTGN |
|---|---|---|
| Share price | $1.39 | $0.2417 |
| Market cap | $9.16M | $10.73M |
| 1-day change | -4.80% | -2.19% |
| YTD return | — | -62.56% |
| 1-year return | — | -93.76% |
| 5-year return | — | -99.66% |
| EPS (TTM) | $-3.65 | $-1.66 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.85 | $5.14 |
| 52-week low | $0.966 | $0.20 |
| Distance from 52-week high | -90.64% | -95.30% |
| Average volume | 230.88K | 12.38M |
| Shares outstanding | 6.59M | 44.38M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
MTVA vs VTGN FAQ
Which is bigger, MetaVia or Vistagen Therapeutics?
Vistagen Therapeutics (VTGN) is larger, with a market capitalization of $10.73M compared with $9.16M for MetaVia (MTVA).
Are MetaVia and Vistagen Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.